Another study, evaluating PARPi sensitivity in over 100 patient-derived xenograft models from BC, showed that low RAD51-FFPE scores displayed a higher accuracy in predicting PARPi response compared to HR gene mutations and genomic HRD analysis, including both myChoice HRD and HRD signature assessment by HRDetect [35]. This evidence concerns the gene RAD51 and breast cancer.